SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 124 filers reported holding SYNDAX PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 0.54 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $1,255,800 | -84.8% | 60,000 | -84.6% | 0.09% | -85.3% |
| Q1 2023 | $8,236,799 | -43.2% | 390,000 | -31.6% | 0.61% | -50.0% |
| Q4 2022 | $14,506,500 | -46.6% | 570,000 | -49.6% | 1.23% | -41.5% |
| Q3 2022 | $27,154,000 | -10.8% | 1,130,000 | -28.6% | 2.10% | -2.3% |
| Q2 2022 | $30,431,000 | +10.7% | 1,581,653 | 0.0% | 2.15% | +46.0% |
| Q1 2022 | $27,489,000 | -10.0% | 1,581,653 | +13.3% | 1.47% | +31.0% |
| Q4 2021 | $30,547,000 | +40.7% | 1,395,492 | +22.9% | 1.12% | +32.7% |
| Q3 2021 | $21,707,000 | +16.4% | 1,135,900 | +4.6% | 0.85% | +31.5% |
| Q2 2021 | $18,644,000 | -0.1% | 1,085,900 | +30.0% | 0.64% | -34.8% |
| Q1 2021 | $18,670,000 | -15.1% | 835,000 | -15.5% | 0.99% | -5.0% |
| Q4 2020 | $21,982,000 | +79.8% | 988,406 | +19.3% | 1.04% | +16.2% |
| Q3 2020 | $12,227,000 | -18.8% | 828,371 | -18.5% | 0.90% | -25.7% |
| Q2 2020 | $15,062,000 | -26.4% | 1,016,371 | -45.5% | 1.20% | 0.0% |
| Q1 2020 | $20,470,000 | +152.1% | 1,866,076 | +101.7% | 1.20% | +29.7% |
| Q4 2019 | $8,121,000 | -7.2% | 925,000 | -21.1% | 0.93% | -4.5% |
| Q3 2019 | $8,751,000 | -41.8% | 1,171,648 | -27.5% | 0.97% | -28.9% |
| Q2 2019 | $15,045,000 | +79.3% | 1,615,955 | +1.1% | 1.37% | +79.8% |
| Q1 2019 | $8,391,000 | +40.4% | 1,598,357 | +19.0% | 0.76% | +110.2% |
| Q4 2018 | $5,976,000 | +41.9% | 1,342,839 | +157.7% | 0.36% | +32.6% |
| Q3 2018 | $4,210,000 | +59.9% | 521,000 | +38.9% | 0.27% | +53.4% |
| Q2 2018 | $2,633,000 | -34.7% | 375,000 | +32.4% | 0.18% | -50.0% |
| Q1 2018 | $4,030,000 | – | 283,230 | – | 0.36% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,600,000 | $52,272,000 | 8.55% |
| Foresite Capital Management IV, LLC | 875,000 | $12,705,000 | 7.06% |
| Aisling Capital Management LP | 1,025,000 | $14,883,000 | 6.13% |
| Saturn V Capital Management LP | 807,969 | $11,731,710 | 4.91% |
| Eversept Partners, LP | 2,596,245 | $37,697,477 | 3.19% |
| ACUTA CAPITAL PARTNERS, LLC | 297,035 | $4,312,948 | 2.89% |
| Paradigm Biocapital Advisors LP | 2,390,077 | $34,703,918 | 2.36% |
| DAFNA Capital Management LLC | 458,373 | $6,655,576 | 2.07% |
| SPHERA FUNDS MANAGEMENT LTD. | 773,061 | $11,224,846 | 2.04% |
| PFM Health Sciences, LP | 2,715,235 | $39,425,212 | 1.86% |